(UroToday.com) It is increasingly well-known that African American (AA) men as a group experience higher incidence of prostate cancer and worse prostate cancer-specific outcomes. The reasons for this are the point of ongoing investigations, with contributors to disparity from biological and non-biological factors. Within the realm of differential biology lie the data that AA men have demonstrated more pronounced prostate-specific antigen (PSA) responses as compared to white counterparts when treated with abiraterone acetate in the metastatic castration-resistant setting (mCRPC),1 and with subsequent prospective studies indicating improved progress-free survival in this same population (as compared to non-Hispanic white patients).2 Dr. Mallika Marar and colleagues sought to determine, retrospectively, whether similar demographic-based differences in the efficacy of abiraterone acetate exist in real-world practice.